Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00413660
Status:
COMPLETED
Last Update Posted:
2013-01-18
First Post:
2006-12-18
Brief Title:
Comparison Of 6 CP-690550 Doses VsPlacebo Each Combined With Methotrexate For The Treatment Of Rheumatoid Arthritis
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 2B Randomized Double Blind Placebo-Controlled Multicenter Study To Compare 6 Dose Regimens Of CP-690550 Vs Placebo Each Combined With Methotrexate Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effectiveness and safety over 6 months of 6 dose regimens of CP-690550 combined with methotrexate for the treatment of adults with active rheumatoid arthritis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None